Advertisement

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Advertisement

Advertisement




Jan
07
Today In Oncology
Novel AI Platform May Help Identify Patients Likely to Benefit Most From Clinical Trials
AI May Improve Ovarian Cancer Diagnoses
AI Tool May Help to Predict Which Patients With Prostate Cancer May Benefit From Focal Therapy
Machine Learning Program May Enhance Transplantation Risk Assessment in Patients With Myelofibrosis
Patient Support Found for AI Use as Second Reader of Mammograms
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo